ABIVAX Société Anonyme (AAVXF)
USD 11.05
(0.0%)
USD 11.05
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 127.37 Million EUR | 132.22% |
| 2022 | 56.53 Million EUR | 32.73% |
| 2021 | 42.59 Million EUR | 11.89% |
| 2020 | 38.07 Million EUR | 14.32% |
| 2019 | 33.3 Million EUR | 74.71% |
| 2018 | 19.06 Million EUR | 34.76% |
| 2017 | 14.14 Million EUR | -22.78% |
| 2016 | 18.31 Million EUR | 2.01% |
| 2015 | 17.95 Million EUR | 107.87% |
| 2014 | 8.63 Million EUR | 18.14% |
| 2013 | 7.31 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 43.39 Million EUR | 0.0% |
| 2024 Q1 | 43.39 Million EUR | -6.02% |
| 2023 Q3 | 47.79 Million EUR | 21.91% |
| 2023 FY | 131.28 Million EUR | 132.22% |
| 2023 Q1 | 22.61 Million EUR | -40.47% |
| 2023 Q2 | 39.2 Million EUR | 73.35% |
| 2023 Q4 | 46.17 Million EUR | -3.4% |
| 2022 Q3 | 18.59 Million EUR | 0.05% |
| 2022 FY | 56.53 Million EUR | 32.73% |
| 2022 Q4 | 37.98 Million EUR | 104.29% |
| 2022 Q2 | 18.58 Million EUR | 76.3% |
| 2022 Q1 | 10.54 Million EUR | -58.76% |
| 2021 Q4 | 25.56 Million EUR | 14.03% |
| 2021 Q1 | 2.97 Million EUR | -87.27% |
| 2021 Q2 | 26.5 Million EUR | 791.81% |
| 2021 FY | 42.59 Million EUR | 11.89% |
| 2021 Q3 | 22.41 Million EUR | -15.4% |
| 2020 Q4 | 23.35 Million EUR | 1605.0% |
| 2020 Q2 | 16.17 Million EUR | 2389.08% |
| 2020 Q3 | 1.36 Million EUR | -91.54% |
| 2020 Q1 | 650 Thousand EUR | -95.95% |
| 2020 FY | 38.07 Million EUR | 14.32% |
| 2019 Q3 | 1.18 Million EUR | -93.09% |
| 2019 Q4 | 16.03 Million EUR | 1251.85% |
| 2019 FY | 33.3 Million EUR | 74.71% |
| 2019 Q1 | 1.34 Million EUR | 5.65% |
| 2019 Q2 | 17.16 Million EUR | 1175.04% |
| 2018 FY | 19.06 Million EUR | 34.76% |
| 2018 Q3 | 1.27 Million EUR | 13.85% |
| 2018 Q2 | 1.11 Million EUR | 0.0% |
| 2018 Q1 | 1.11 Million EUR | 10.57% |
| 2018 Q4 | 1.27 Million EUR | 0.0% |
| 2017 Q1 | 929.5 Thousand EUR | 3.22% |
| 2017 Q2 | 929.5 Thousand EUR | 0.0% |
| 2017 Q3 | 1.01 Million EUR | 8.88% |
| 2017 Q4 | 1.01 Million EUR | 0.0% |
| 2017 FY | 14.14 Million EUR | -22.78% |
| 2016 Q2 | 900.99 Thousand EUR | 0.0% |
| 2016 FY | 18.31 Million EUR | 2.01% |
| 2016 Q3 | 900.49 Thousand EUR | -0.06% |
| 2016 Q1 | 900.99 Thousand EUR | -30.34% |
| 2016 Q4 | 900.49 Thousand EUR | 0.0% |
| 2015 Q1 | 805.49 Thousand EUR | -33.01% |
| 2015 Q2 | 805.49 Thousand EUR | 0.0% |
| 2015 Q3 | 1.29 Million EUR | 60.58% |
| 2015 Q4 | 1.29 Million EUR | 0.0% |
| 2015 FY | 17.95 Million EUR | 107.87% |
| 2014 FY | 8.63 Million EUR | 18.14% |
| 2014 Q4 | 1.2 Million EUR | 0.0% |
| 2014 Q2 | 151.5 Thousand EUR | 0.0% |
| 2014 Q1 | 151.5 Thousand EUR | 0.0% |
| 2014 Q3 | 1.2 Million EUR | 693.73% |
| 2013 FY | 7.31 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -46.772% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -2490.042% |
| SQZ Biotechnologies Company | 85.61 Million USD | -48.771% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -331.009% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -241.897% |
| Mesoblast Limited | 5.9 Million USD | -2058.184% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -8380.996% |
| Genus plc | 147.7 Million USD | 13.76% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -1350.878% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -9394.724% |
| Marizyme, Inc. | 19.23 Million USD | -562.043% |
| ContraFect Corporation | 56.88 Million USD | -123.903% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -1427.473% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -2789.215% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -8513.75% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -4267.824% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -4464.864% |
| MultiCell Technologies, Inc. | 567.42 USD | -22448174.647% |
| Accustem Sciences Inc. | 3.74 Million USD | -3299.94% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -48.206% |
| EV Biologics, Inc. | 531.96 Thousand USD | -23844.567% |
| Q BioMed Inc. | 3.43 Million USD | -3606.424% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -415.379% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -32596.899% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -4747.762% |
| Biomind Labs Inc. | 994.18 Thousand USD | -12712.141% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 43.512% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -1796.036% |
| Skye Bioscience, Inc. | 13.54 Million USD | -840.214% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -6117.391% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 509604.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -2426.277% |
| IMV Inc. | 37.7 Million USD | -237.785% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -695.591% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -6841.112% |
| GB Sciences, Inc. | 1.42 Million USD | -8866.927% |
| Alpha Cognition Inc. | 9.7 Million USD | -1212.397% |
| HST Global, Inc. | 140.9 Thousand USD | -90297.212% |
| CSL Limited | 3.44 Billion USD | 96.307% |
| Halberd Corporation | 74.84 Thousand USD | -170093.207% |
| Enzolytics Inc. | 2.17 Million USD | -5744.257% |
| Resverlogix Corp. | 12.71 Million USD | -902.014% |
| Affymax, Inc. | 39.38 Million USD | -223.404% |
| SYBLEU INC | 160.87 Thousand USD | -79076.509% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -3389.078% |
| argenx SE | 1.53 Billion USD | 91.694% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -121.755% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -12100.766% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -7965.065% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -3640.875% |
| AVAX Technologies, Inc. | 7.31 Million USD | -1642.427% |
| Zenith Capital Corp. | 8.94 Million USD | -1324.31% |
| Genscript Biotech Corporation | 825.34 Million USD | 84.567% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -731063.538% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -5087.762% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -74167.823% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -28.235% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -7138.597% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -6359.118% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -6732.12% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -1072.136% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -6531.038% |
| BioStem Technologies, Inc. | 22.97 Million USD | -454.416% |
| ONE Bio Corp. | 6.44 Million USD | -1876.694% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -70085.415% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -9438.194% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -11223.217% |
| Agentix Corp. | 1.37 Million USD | -9185.616% |
| LadRx Corporation | 3.81 Million USD | -3241.631% |
| Cell Source, Inc. | 4.32 Million USD | -2844.874% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -30557.626% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -13692.596% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -13692.596% |
| NovAccess Global Inc. | 2.46 Million USD | -5063.694% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -5196.445% |
| Itoco Inc. | 919.14 Thousand USD | -13758.127% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -2905.275% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -11283.021% |
| Kadimastem Ltd | 2.41 Million USD | -5185.066% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -48567.691% |
| CytoDyn Inc. | 18.05 Million USD | -605.372% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -505982.88% |
| Mobile Lads Corp. | 554.54 Thousand USD | -22869.42% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -57777.662% |
| Qrons Inc. | 643.67 Thousand USD | -19688.807% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -8871.455% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -5612.238% |
| Rebus Holdings, Inc. | 664 Thousand USD | -19083.133% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -6912.861% |
| International Stem Cell Corporation | 5.27 Million USD | -2316.543% |
| Bioxytran, Inc. | 3.82 Million USD | -3234.322% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -241866.491% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -626041.67% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -251.227% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -7772.435% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -17210.402% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -3994.375% |
| Neutra Corp. | 243.82 Thousand USD | -52141.603% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -629.656% |
| PureTech Health plc | 144.59 Million USD | 11.91% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -521.653% |
| IXICO plc | 4.7 Million USD | -2606.097% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -1347.948% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -8.177% |
| CSL Limited | 3.89 Billion USD | 96.728% |
| Cellectis S.A. | 97.32 Million USD | -30.884% |